BioLife Products are Currently being used in approximately 200 Pre-Clinical Validation Projects and Clinical Trials; Report Available here: www.lifescicapital.com/equity-research/biolife-solutions/
NEW YORK, NY / ACCESSWIRE / August 3, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioLife Solutions, Inc. (NasdaqCM: BLFS), a leading supplier of products offering hypothermic storage, shipping, and cryopreservation solutions. The products include cell preservation media that offer superior performance as compared to traditional methods. The Company is also preparing to launch the biologistex(SM) cold chain management service that features a mobile-enabled tracking system coupled with the evo(R) line of precision, electronically trackable thermal shipping containers for cells, tissues and organs.
BioLife Solutions has reported steady revenue growth in its core product line, reporting $4.9 million in revenue for 2014 compared to $3.9 million in 2013. The Company is on track to continue this expansion, having already recorded $2.9 million in product revenue for the first half of 2015. BioLife products are deeply embedded in the development of cell based therapies, as evidenced by their use in 21 Phase III studies and approximately 200 pre-clinical validation projects and clinical trials. The Company believes that each successful clinical program has the potential to lead to between $0.5 and $2 million in annual revenue. BioLife is well positioned to capture the overall growth in cell-based therapies, including CAR-T programs for cancer that are currently generating significant excitement in the oncology community.
In a 28 page Initiation Report LifeSci Capital explains the breadth of BioLife's offerings, data supporting the use of the products in regenerative medicine, and the market opportunity.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioLife Solutions as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com
SOURCE: LifeSci Capital